期刊文献+

水飞蓟宾磷脂复合物自微乳给药系统研究

Study of SLB phospholipid complex Self-microemulsifying Drug Delivery System
下载PDF
导出
摘要 目的研制水飞蓟宾(SLB)磷脂复合物自微乳化胶囊并对其进行体外评价。方法通过单因素考察结合正交设计将SLB制成磷脂复合物,测定了该复合物的溶解度和油水分配系数,进一步制成自微乳给药系统。结果 SLB磷脂复合物的最佳工艺条件为,反应温度50℃,反应时间2 h,比例1∶2。按此最佳工艺条件制备SLB磷脂复合物,复合率为100%,其溶解度和油水分配系数分别为126.3μg.mL-1,166.64,其最佳自微乳给药系统(PMC)组成及比例为,复合物∶油酸乙酯∶吐温80∶丙二醇=12∶30∶45∶13。按最佳处方制备的SLB磷脂复合物-PMC在人工胃液中36 min内累积溶出百分率已达到80%。结论将水飞蓟宾制成磷脂复合物自微乳化胶囊能显著提高其体外溶出度。 OBJECTIVE The formulation design and vitro evaluation of selfmicroemulsifying drug delivery system(SMEDDS) for silibinin(SLB) phospholipid complex.METHODS SLB was prepared into phospholipid complex by single factor investigation and orthogonal design.The solubility and O/W coefficient of SLB phospholipid complex were determined.Further,the SLB phospholipid complex was formulated into SMEDDS.RESULTS The best productive condition of SLB phospholipid complex were 50℃ reaction temperature,2h reaction time,the ratio of SLB and phospholipid was 1∶2.the complex ratio was 100% following above to prepared.The solubility and O/W coefficient of distribution of SLB phospholipid complex were 126.3 μg·mL-1 and 166.64,respectively.the optimum formulations of SLB phospholipid complex-SMEDDS were composed of complex,ethyl oleate,tween 80 and propylene glycol,with the ratio of 12∶30∶45∶13.The dissolution of the SLB complex-PMC in artificial gastric juice was 80% in 36 min.CONCLUSION SLB phospholipid complex-SMEDDS can improve the dissolution of SLB.
出处 《海峡药学》 2010年第6期19-23,共5页 Strait Pharmaceutical Journal
基金 广东省科技厅重点引导项目(2005B10401004)
关键词 水飞蓟宾 磷脂复合物 自微乳化释药系统 溶解度 油水分配系数溶出度 Silibinin(SLB) Phospholipid complex Self-microemulsifying Drug Delivery System Dissolution O/W coefficient of distribution Solubility
  • 相关文献

参考文献12

  • 1Flora K,Hahn M,Rose H,et al.Milk thistle (Silybum marianum)for the therapy of liver disease[J].AmJ Gastroenterol,1998,93(2):139-142.
  • 2Luper S.A review of plants used in the treatment of liver disease:part 1[J].Altern Med Rev,1998,3(6):410-412.
  • 3GABETTA E,BOMBAROELLI E,PIFFERL G Complexes of flavanolignanes with phospholipids,preparation there of and associated pharmaceutical composition.Patent No.,0209038[P] 1987-01-21.
  • 4WU J M,CHEN D W,ZHANG R H,et al.The review of the pharmaceutical study on the natural active component-phospholipid complex[J].Chin Pharm J.1998,33 (1):9-11.
  • 5廉洁,王伯初.药物磷脂复合物工艺评价标准及应用研究进展[J].生物技术通讯,2006,17(5):830-833. 被引量:24
  • 6许建文,张光军,陈正跃.水飞蓟宾-卵磷脂复合物制备工艺比较[J].中国生化药物杂志,2002,23(5):245-246. 被引量:14
  • 7肖衍宇,宋赟梅,陈志鹏,平其能.水飞蓟宾磷脂复合物的制备与大鼠生物利用度的研究[J].药学学报,2005,40(7):611-617. 被引量:27
  • 8Gabetta B,Bombardelli E,Pifferl G Complexes of flavanolignanes with phospholipids,preparation thereof and associated pharmaceutical compositions.European Patent Application 0,209,038.1987-01-21.
  • 9Bombardelli E,Bianchetti G.Pharmaceutical cosmetic compositions containing complexes of flavanolignans with phospholipids.European Patent Application 0,300,282.1989-01-25.
  • 10Bombardelli E,Spelta M.Aging skin:protective effect of silymarinPhytosome.Fitoterapia,1991,62(2):115-126.

二级参考文献21

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部